Pfizer's stock surged 1.5% after its respiratory syncytial virus vaccine Abrysvo, showed positive results in a trial for high-risk adults under 60. It was also well tolerated, producing similar immune responses to those seen in older adults.
The trial enrolled 681 adults with conditions such as asthma and diabetes. Pfizer said it would seek expanded approval for adults 18 through 59 based on the findings. RSV is a common cause of pneumonia in toddlers and older adults. But experts are divided over the vaccine's clinical benefit for most people in both high-risk groups.
Comments